logo-loader
CelLBxHealth PLC

Master Services Agreement with Swiss biotech co

RNS Number : 7574Z
CelLBxHealth PLC
21 October 2026
 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is in the public domain.

 


 

CelLBxHealth plc

 (“CelLBxHealth” or "the Company")

 

CelLBxHealth signs Master Services Agreement with a Swiss biotech company for a

 Radio-Pharmaceutical Clinical Study

 

Guildford, UK and Plymouth Meeting, U.S. - 21 October 2026 - CelLBxHealth plc (AIM: CLBX), a circulating tumour cell (CTC) intelligence company specialising in CTC solutions for use in research, drug development and clinical oncology, announces that it has entered into a Master Services Agreement (“MSA”), together with a Statement of Work, with a Swiss biotech company.

 

Dr. Jan Groen, Executive Chairman of CelLBxHealth, commented:

“We are pleased to support the programme. This study brings together our CTC enrichment and analysis capabilities with a targeted radio-pharmaceutical development programme. We aim to generate data that may help the Swiss biotech company explore the role of CTCs in its future research and clinical applications.”

 

In 2025, the market size of the radioligand-therapy market was had a value of ~ US$3.0 billion, increasing to between US$10.9 billion and US$15.9 billion by 2035, representing annual growth of approximately 13–18%. (source: SNS Inside pvt ltd).

 

For further information:

 

CelLBxHealth plc

Jan Groen, Executive Chairman

investor@cellbxhealth.com

via Walbrook PR

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

+44 (0)20 7220 0500

Walbrook PR (Investor and Media Relations)

Paul McManus / Alice Woodings

Tel: +44 (0)20 7933 8780 or CelLBx@walbrookpr.com

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

Notes for editors 

 

About CelLBxHealth plc

CelLBxHealth plc is a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows. Commercial focus span three revenue streams — Product Sales through CRO, clinical lab partnerships and laboratory services including clinical trial support and assay development.

 

For more information, visit https://cellbxhealth.com/.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRFLFSDISLIFIR
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

London BTC Company, CelLBxHealth, Anglo Asian Mining, Galliford Try,...

London BTC Company Ltd (LSE:BTC, OTCQB:VINZF) has staked 36 mineral claims at its new Black Star gold-silver project in Nevada, with surface samples returning up to 16.23 grams per tonne gold. It's the company's fourth Nevada project and sits just 16 miles from the 16.4 million ounce Hycroft...

on 07/15/2026

3 min read